Mayo Clinic Laboratories offers a new test that builds upon the individual NF155 test to help physicians with early diagnosis and treatment optimization.

Yi Lin, M.D., Ph.D., associate professor of medicine at Mayo Clinic and medical director for the Cellular Therapy Program, led a survey to investigate the scope of this problem, which has not been covered in literature thus far. The findings were published as an abstract at the recent annual meeting of the American Society of Clinical Oncology.

Inflammatory bowel disease (IBD) serology testing at Mayo Clinic Laboratories can help physicians distinguish between an ulcerative colitis diagnosis and a Crohn’s disease diagnosis. Melissa Snyder, Ph.D., explains in a “Test in Focus” episode of the “Answers From the Lab” podcast how the IBDP2 serology panel can make this important distinction after first-line testing has failed.

Clinical trials offer expanded treatment for ovarian cancer.

New Mayo Clinic research suggests the use of artificial intelligence can help inform physicians on the selection, use, and dosing of antidepressants for children and adolescents with major depressive disorder.

Researchers find gut microbiome, host gene impact gastrointestinal disorders.

Nikola Baumann, Ph.D., highlights the new NASH-FibroTest, available through Mayo Clinic Laboratories, in a recent “Test in Focus” podcast. The NASH-FibroTest uses three noninvasive tests — NashTest 2, SteatoTest 2, and FibroTest — that allow clinicians to diagnose and make follow-up treatment decisions for patients with nonalcoholic steatohepatitis (NASH).

“NFLC is specific to neurons and usually isn’t found in circulation,” says Alicia Algeciras-Schimnich, Ph.D. “But following neuronal injury, NFLC is released into cerebral spinal fluid and then into blood, where it can be detected.”

Closing the gap on accessible, inhibition-resistant CAR-T cell therapy.

Cherisse Marcou, Ph.D., and Marissa Ellingson, M.S., CGC, discuss whole exome sequencing (WES) at Mayo Clinic Laboratories. The comprehensive evaluation uses next-generation sequencing to detect for single nucleotide variants, small insertions or deletions, and copy number variants on approximately 20,000 genes, enabling precision answers to accurately diagnose, manage, and treat patients with identified inherited illness.

T-cell lymphoma is a group of cancers derived from T-cells, which are cells of the immune system that are critical to immune function. Because there are more than 30 identified subtypes of T-cell lymphoma, it can be difficult to make a definitive diagnosis.

Mayo Clinic Laboratories offers a comprehensive genomic profiling panel for solid tumors called the MayoComplete Solid Tumor Panel. This next-generation sequencing assay — Mayo Clinic Laboratories’ most comprehensive genetic profiling assay to date — assesses for mutations in 514 cancer-related genes that have been shown to have clinical importance.